Key points
- First commercial conversion from SAPPHIRE Study
- Five-year agreement with minimum contracted value of $0.5M
- Largest U.S. deployment for Artrya to date
Full summary
Artrya Limited (ASX: AYA), a medical technology company, has signed a five-year commercial agreement with Huntsville Hospital Health System (HH Health). This agreement marks the first conversion of a SAPPHIRE Study participant into a commercial customer and is a significant milestone for Artrya's U.S. commercial strategy. The agreement includes a minimum contracted value of $0.5M for Salix Coronary Anatomy, with additional fee-per-scan revenue from Salix Coronary Plaque and Salix Coronary Flow once FDA cleared. Salix Coronary Anatomy will be integrated into applicable clinical workflows across HH Health's 15-hospital network, making this the largest U.S. deployment for Artrya to date.
Guidance
Minimum contracted value of $0.5M for Salix Coronary Anatomy
Outlook
Artrya aims to continue progressing its relationships with other SAPPHIRE participants and expand its broader U.S. commercial activities.